Lui, David Tak Wai; Xiong, Xi; Cheung, Ching-Lung; Lai, Francisco Tsz Tsun; Li, Xue; Wan, Eric Yuk Fai; Chui, Celine Sze Ling; Chan, Esther Wai Yin; Cheng, Franco Wing Tak; Li, Lanlan; +6 more... Chung, Matthew Shing Hin; Lee, Chi Ho; Woo, Yu Cho; Tan, Kathryn Choon Beng; Wong, Carlos King Ho; Wong, Ian Chi Kei; (2024) Risk of Incident Thyroid Dysfunction in the Post-Acute Phase of COVID-19: A Population-Based Cohort Study in Hong Kong. Endocrine practice, 30 (6). pp. 528-536. ISSN 1530-891X DOI: https://doi.org/10.1016/j.eprac.2024.03.389
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
OBJECTIVE: The evidence of thyroid dysfunction in the post-acute phase of SARS-CoV-2 infection is limited. This study aimed to evaluate the risk of incident thyroid dysfunction in the post-acute phase of COVID-19. METHODS: This retrospective, propensity-score matched, population-based study included COVID-19 patients and non-COVID-19 individuals between January 2020 and March 2022, identified from the electronic medical records of the Hong Kong Hospital Authority. The cohort was followed up until the occurrence of outcomes, death, or 31 January 2023, whichever came first. Patients with COVID-19 were 1:1 matched to controls based on various variables. The primary outcome was a composite of thyroid dysfunction (hyperthyroidism, hypothyroidism, initiation of antithyroid drug or levothyroxine, and thyroiditis). Cox regression was employed to evaluate the risk of incident thyroid dysfunction during the post-acute phase. RESULTS: A total of 84 034 COVID-19 survivors and 84 034 matched controls were identified. Upon a median follow-up of 303 days, there was no significant increase in the risk of diagnosed thyroid dysfunction in the post-acute phase of COVID-19 (hazard ratio [HR] 1.058, 95% confidence interval 0.979-1.144, P = .154). Regarding the secondary outcomes, patients with COVID-19 did not have increased risk of hyperthyroidism (HR 1.061, P = .345), hypothyroidism (HR 1.062, P = .255), initiation of antithyroid drug (HR 1.302, P = .070), initiation of levothyroxine (HR 1.086, P = .426), or thyroiditis (P = .252). Subgroup and sensitivity analyses were largely consistent with the main analyses. CONCLUSION: Our population-based cohort study provided important reassuring data that COVID-19 was unlikely to be associated with persistent effects on thyroid function.
Item Type | Article |
---|---|
Faculty and Department | Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology & Dynamics (2023-) |
Research Centre | Covid-19 Research |
PubMed ID | 38552902 |
Elements ID | 224412 |
Official URL | http://dx.doi.org/10.1016/j.eprac.2024.03.389 |
Downloads
Embargo Date: 27 March 2025
Restricted to: Repository staff only
Filename: Lui-etal-2024-Risk-of-incident-thyroid-dysfunction.pdf
Description: This is an author accepted manuscript version of an article accepted for publication, and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it.
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Embargo Date: 27 March 2025
Restricted to: Repository staff only
Filename: Tables.docx
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Embargo Date: 27 March 2025
Restricted to: Repository staff only
Filename: Figure 1.tif
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0
Embargo Date: 27 March 2025
Restricted to: Repository staff only
Filename: Figure 2.tif
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0